RPS6KB1 and metabolic dysfunction-associated steatotic liver disease: To assess the role of the mTOR signaling pathway in the occurrence and development of NAFLD, we examined whether treatment with RAPA and PF-4708671 (specific inhibitors of mTOR and S6K1, respectively) can inhibit intracellular lipid accumulation in HepG2 cells.